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Abstract 
 
Fenugreek (Trigonella foenum-graecum L.) was initially introduced to Alberta as a spice and forage 
crop. Numerous animal and clinical studies have associated the medicinal properties of the plant with 
galactomannan, diosgenin and 4-hydroxyisoleucine, the three major bioactive compounds found in 
fenugreek seed. These bioactive molecules have been demonstrated to regulate plasma cholesterol 
levels, reduce plasma triglyceride concentrations and stimulate insulin secretion for blood glucose 
metabolism. Fourteen advanced lines grown satisfactorily in southern Alberta were selected for 
quantification of these compounds over two harvest seasons. These lines were grown at three locations 
(Brooks, Bow Island and Lethbridge) in southern Alberta under two growing conditions (rain-fed or 
irrigated). In this study we report on five different seed lines which possessed a high galactomannan 
yield during the study; i.e., seed lines F75, L3312, CDC Quatro, F80 and L3308. Seed line F75 was the 
only line that performed well across all locations and growing conditions. It was observed that seed 
yield had a greater influence on galactomannan yield compared to seed galactomannan content. This 
suggests that cultivation of fenugreek plants for neutraceutical purposes should emphasize lines with 
high seed yield, as galactomannan content does not vary significantly among lines. An understanding 
of the interaction of bioactive compound content with respective ecotypes will assist in the selection of 
lines for their economic potential in the functional food and natural health product industry. 
 
 
Introduction  
 
Fenugreek is a diploid (2n=16) leguminous crop native to the Indian subcontinent and the East 
Mediterranean region. It has been used for centuries as a medicinal plant as well as a cooking 
ingredient to impart flavor, aroma and color to foods (Petropoulos, 2002). Fenugreek seeds are known 
to contain high amounts of dietary soluble fiber (45-50%; 13-20% of which is galactomannan), protein 
(20-36%), including a free amino acid called 4-hydroxyisoleucine, oil (5-6%), ash (3%), starch (2%), 
sugar (1%) (Slinkard et al., 2006) and diosgenin, a steroidal compound reported to range between 0.8 
and 2.2% on a dry weight basis (Fazli and Hardman 1968; Taylor et al., 1997). Galactomannan, 
diosgenin, and 4-hydroxyisoleucine are all considered bioactive compounds and have been 
individually studied using animal and clinical trials to test for potential health benefits. These benefits 
include regulation of plasma cholesterol levels, reduction of triglyceride levels and insulin stimulation 
for control of blood glucose levels (Al-Habori and Rahman, 2002). 
 
Galactomannan is a plant polysaccharide which contains a mannan backbone substituted with 
galactosyl residues; structurally it consists of a 1→4 linked β-D-mannosyl backbone with single-unit 
galactose side-chains α-linked at the C-6 oxygen (Bhaumick, 2006). Health benefits of galactomanan 
are mainly associated with  the reduction of plasma glucose levels (Sharma, 1986; Madar et al., 1988; 
Madar and Shomer, 1990) and cholesterol concentrations (Sharma et al., 1996; Ribes et al., 1987). 
This large molecular polysaccharide has been postulated to regulate plasma glucose levels by delaying 
gastric emptying and by interfering with glucose absorption in the gut (Madar, 1984). Formation of a 
physical barrier by galactomannan that may aid inhibition of bile salt absorption in the gut has been 
associated with fenugreek’s hypocholesterolaemic properties (Madar and Shomer, 1990). Fenugreek 
galactomannan is unique in that it possesses a galactose to mannose ratio of 1:1 (Reid and Meier, 1970) 
 
Little is known about variation in the content of bioactive compounds in the various lines of fenugreek, 
and the effects of environment and land management practices such as irrigation and dry land farming 
on bioactive compound production in the plants. This study will hopefully provide insight into the 
production of bioactive compounds in different fenugreek lines and their ecotypes, as well as providing 
an estimate of the economic potential for each cultivar when grown under different environmental 
conditions 
 
 
Materials and Methods 
 
Fenugreek seeds used in the study were obtained from eleven lines and three cultivars (AC Amber, 
CDC Quatro and Tristar) grown at three locations (Lethbridge, Brooks and Bow Island), under both 
rain-fed and irrigated conditions. Each plot was 4.5 m long and consisted of 4 rows spaced 30 cm apart. 
Lines/cultivars were arranged using a Randomized Complete Block Design (RCBD) with two 
replicates at each location-condition combination. Moisture accumulation levels for the three locations 
are shown in Table 1.  
 
Table 1. Moisture accumulation levels for the three locations in 2006. 
Accumulation (mm)  
Location 
 Precipitation Irrigation Total 
RF 157.4 - 157.4 Brooks 
IR 166.0 150.0 316.0 
RF 114.8 - 114.8 Bow Island 
IR 151.2 178.3 329.5 
RF 140.5 - 140.5 Lethbridge 
IR 140.5 152.4 292.9 
 * RF = rain-fed; IR = irrigated 
 
Seeds were mechanically harvested and cleaned to remove dirt, dust, stones and weeds. They were 
placed in a plant dryer for approximately 1 week at 29°C to 32°C to remove surface moisture prior to 
being stored in a dry and cool environment until use. 
 
Galactomannan content was determined using an enzymatic assay kit purchased from Megazyme 
International Ltd. This procedure involved hydrolysis of the large molecule to release free galactose 
into solution. Quantification was achieved through a redox reaction with nicotinamide adenine 
dinucleotide (NAD+) yielding NADH and the lactone form of galactose, followed by UV-absorbance 
detection of NADH to calculate the galactomannan content assuming a galactose/mannose ratio of 1:1. 
 
Results and Discussion 
 
Quantification of galactomannan is expressed as galactomannan yield (kg/ha) and was determined as 
the product of seed yield (kg/ha) * galactomannan content (% dry weight basis). The top performing 
cultivars / lines are listed in Table 2, along with their respective seed yield and galactomannan contents. 
F75 was identified as the sole line to perform well across all locations under both growing conditions. 
 
Table 2. Top five performing cultivars / lines across three locations under both growing conditions. 
Cultivar/Line Seed yield (kg/ha) Galactomannan 
content (%) 
Galactomannan 
yield (kg/ha) 
F75 2653 18.8 493 
L3312 2336 19.0 458 
CDC Quatro 2357 18.4 447 
F80 2244 19.2 433 
L3308 2200 18.8 421 
 
 
The mean galactomannan content for Brooks was 17.6% (rain-fed) and 18.7% (irrigated); for Bow 
Island 18.0% (rain-fed) and 21.6% (irrigated); and for Lethbridge 15.9% (rain-fed) and 17.1% 
(irrigated). The average galactomannan content for all locations and growing environments was 18.2%. 
Seeds from Brooks (rain-fed) produced the highest galactomannan yield (kg/ha) at 589 kg/ha while 
seeds from Lethbridge (irrigated) gave the lowest galactomannan yield at 123 kg/ha. The effect of 
growing conditions on the galactomannan content of the eleven lines and three cultivars tested was 
highly variable.   
 
It was observed that seed yield was a greater influence on total galactomannan yield than the 
galactomannan concentration of the seed. This may be due to the fact that seed yield is highly 
dependent on the growing environment and weather variation. Also, the galactomannan content did not 
vary significantly among lines and cultivars (mean = 18.2%, std. dev. = 2.0%). Based on these 
observations, selected lines should be recommended for cultivation based on their high seed yield 
rather than on their galactomannan content, in order to achieve a satisfactory galactomannan yield for 
commercial extraction. 
 
Galactomannan is concentrated in the seed coat while diosgenin and 4-hydroxyisoleucine is 
predominantly present in the endosperm. It is hypothesized that the galactomannan content would be 
higher in a small seed with a large seed coat surface area to volume ratio. Development of a thorough 
understanding of the effect of agricultural practices on levels of biochemical compounds such as 
galactomannan will hopefully help expand the economic potential of fenugreek in Canada. 
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